Nils Skajaa, Szimonetta K. Szépligeti, Fei Xue, Henrik Toft Sørensen, Vera Ehrenstein, Osa Eisele, Kasper Adelborg June 15, 2019


Prevalence of migraine is high during the reproductive age. Although migraine often improves during pregnancy, the risk of adverse pregnancy, birth, neonatal, and neurological outcomes in mother and offspring remains poorly understood.


To investigate the associations between maternal migraine and risks of adverse pregnancy outcomes in the mother, and birth, neonatal and postnatal outcomes in the offspring.… Read More...

Elizabeth M. Trahan, Janyna M. Mercado June 15, 2019


To explore the neuropsychological correlates and implications of familial hemiplegic migraines (FHMs).


FMH is a rare, autosomal dominant subtype of migraine that only occurs in 0.01% of the population. Little is known about the neuropsychological impact of FHMs; however, cognitive impairment associated with cerebellar syndrome has been identified in some cases.… Read More...

Richard Hargreaves, Jes Olesen June 15, 2019

Several lines of evidence pointed to an important role for CGRP in migraine. These included the anatomic colocalization of CGRP and its receptor in sensory fibers innervating pain‐producing meningeal blood vessels, its release by trigeminal stimulation, the observation of elevated CGRP in the cranial circulation during migraine with normalization concomitant with headache relief by sumatriptan, and translational studies with intravenous (IV) CGRP that evoked migraine only in migraineurs.… Read More...

Lijun Liu, Yongpeng Yu, Jian He, Lei Guo, Hong Li, Jijun Teng June 15, 2019


Multiple studies have evaluated the associations between 5,10‐methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms and migraine risk with conflicting results. Therefore, we conducted a meta‐analysis on this theme.


We searched the electronic databases of PubMed, EmBase, ScienceDirect, and Cochrane Library for all relevant studies published until April 6, 2018.… Read More...

Halil Can Alaydin, Doga Vuralli, Yeliz Keceli, Ezgi Can, Bulent Cengiz, Hayrunnisa Bolay June 15, 2019


Background and Objective

Migraine attacks disrupt sensory information processing and may also disturb sensorimotor integration. This prospective pilot study aimed to assess the sensorimotor integration and inhibitory circuitry in the sensorimotor cortex using short‐latency afferent inhibition (SAI) paradigm in migraine.… Read More...

Virginia L. Stauffer, Shufang Wang, Menelaos Voulgaropoulos, Vladimir Skljarevski, Amy Kovacik, Sheena K. Aurora June 15, 2019


We examined the efficacy and safety of galcanezumab after treatment cessation in randomized double‐blind, placebo‐controlled, migraine prevention studies (EVOLVE‐1; EVOLVE‐2).


Galcanezumab is indicated for migraine prevention in adults.


Adults with episodic migraine were enrolled into EVOLVE‐1 and EVOLVE‐2, which randomized 858 and 915 patients, respectively, to galcanezumab 120 mg (an initial 240‐mg loading dose), galcanezumab 240 mg, or placebo, administered subcutaneously once monthly for 6 months.… Read More...

Andoird App